Celyad Oncology is a biotechnology company dedicated to pioneering research and development in the field of chimeric antigen receptor (CAR) T-cell therapies for cancer. Utilizing their extensive knowledge of immunology, innovative technology platforms, and a modular design approach to drug discovery, Celyad Oncology is at the forefront of next-generation cellular immunotherapies. Their pipeline includes a range of allogeneic and autologous CAR T-cell therapy candidates, offering hope for those fighting cancer.

By harnessing the power of the body's own immune system, these novel therapies have the potential to revolutionize cancer treatment. Celyad Oncology demonstrates their commitment to innovation through their constant pursuit of scientific advancements. Their ongoing research and discoveries are published in scientific publications, ensuring transparency and accountability.

Stay up to date with Celyad Oncology's groundbreaking developments by following their newsroom, where they release press releases and event information. For investors, the company provides comprehensive information on analyst coverage, corporate governance, and regulated information. Join the fight against cancer with Celyad Oncology, a leading force in the field of CAR T-cell therapies